Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have earned an average recommendation of “Buy” from the fourteen brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $32.2727.

A number of equities analysts have commented on DNLI shares. Morgan Stanley restated an “overweight” rating and set a $40.00 price objective on shares of Denali Therapeutics in a research report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. JPMorgan Chase & Co. increased their target price on shares of Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Wedbush decreased their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, December 11th. Finally, Stifel Nicolaus set a $37.00 price target on Denali Therapeutics in a report on Monday, November 17th.

Denali Therapeutics Trading Down 2.1%

Shares of Denali Therapeutics stock opened at $18.77 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $23.77. The company’s fifty day moving average is $18.54 and its two-hundred day moving average is $16.62. The company has a market capitalization of $2.75 billion, a P/E ratio of -6.45 and a beta of 1.02.

Insiders Place Their Bets

In other Denali Therapeutics news, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $580,767.00. Following the sale, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. This trade represents a 5.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 12.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Denali Therapeutics by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after buying an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Denali Therapeutics by 58.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock valued at $22,732,000 after acquiring an additional 614,555 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of Denali Therapeutics by 11.0% during the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock valued at $281,000 after acquiring an additional 2,052 shares during the last quarter. Woodline Partners LP boosted its stake in shares of Denali Therapeutics by 13.5% during the first quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock valued at $1,543,000 after acquiring an additional 13,517 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in Denali Therapeutics during the 2nd quarter worth about $214,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.